Latest News and Press Releases

K92 Mining announces major expansion of Arakompa AR1 high-grade zone and delineation of substantial near-surface high-grade bulk tonnage zone

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and...

Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at...

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for...

Austin, TX, USA, June 03, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “CRISPR-based Gene Editing Market Size, Trends and Insights By Product (Kits and...

MONTREAL, June 02, 2026 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; NASDAQ: AYA) (“Aya” or the “Corporation”) is pleased to announce high-grade silver drill results from its at-depth...

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN...

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses observed at higher dose levels of LB2102 with an ORR of...

High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides difficile bacteria and spores Allschwil, Switzerland – June 1, 2026Idorsia Ltd...

Taurus Meds online TRT claims and Taurus Charge 4-in-1 ED evaluated: $49 intake, $149/mo TRT, $129.90 sublingual ED, clinician-prescribed.